Walpar Nutrition (WALPAR)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding at 68.61% aligns management with minority shareholders
• ROCE of 16.08% indicates reasonable capital efficiency
• Sales growth of 12.17% shows some underlying demand traction
• Microcap pharma positioning could offer niche opportunities if execution improves

Concerns

• Zero profit growth despite 12.17% sales growth signals margin or cost pressure
• Piotroski F-Score of 4/9 points to weak financial health
• No dividend yield, so returns depend entirely on price appreciation
• Missing book value, ROE, and debt-equity data limits fundamental analysis; P/E of 18.34 is not cheap for flat earnings

AI Analysis

At ₹38, Walpar Nutrition carries a market cap of just ₹43 crore. That is a microcap, and in this zone Mr. Market can misprice, but also mislead. The P/E of 18.34 is not demanding for a pharmaceutical business if earnings are growing; yet reported profit growth is flat at 0.00%, while sales have grown 12.17%. That divergence tells me the company is not converting revenue into profits efficiently. ROCE of 16.08% is respectable, but without return on equity or book value disclosed, I cannot judge true shareholder value creation. The Piotroski F-score of 4 out of 9 is a red flag; it suggests weak financial health and perhaps deteriorating fundamentals, not a business I can trust blindly. On the positive side, promoter holding at 68.61% aligns owners with minority shareholders. The P/E-to-growth ratio of 1.51, if we even use sales growth as a proxy, offers no obvious bargain; with zero profit growth, the effective PEG is far less attractive. Dividend yield is nil, so the only possible return comes from business appreciation, which is far from assured. There is no margin of safety at current levels given the lack of book value and ROE data. I would want to know why profits are stagnant despite 12% sales growth, and why the F-score is so weak. The 52-week range of ₹21.25 to ₹50.60 shows the stock has been a speculative vehicle. In Buffett's game, clarity and certainty matter more than action. This one doesn't meet my quality test.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer